The current Ebola outbreak
Following recent international concern surrounding Ebola outbreaks in Central Africa, research efforts are increasingly focused on improving immune monitoring, vaccine development, and epitope characterization across different Ebola virus species and strains.
In particular, attention has recently turned to the Bundibugyo ebolavirus strain following outbreaks in Uganda and the Democratic Republic of the Congo. Unlike Zaire ebolavirus, there are currently no approved vaccines or therapeutics specifically targeting the Bundibugyo strain, highlighting the urgent need for expanded research into cross-reactive immune responses, novel vaccine targets, and improved diagnostic strategies.
This is where our peptides come in!
JPT supports these efforts with high-quality peptide tools covering Zaire ebolavirus proteins for infectious disease and vaccine research applications. Our peptide products enable researchers to characterize antigen-specific immune responses, identify relevant B- and T-cell epitopes, monitor vaccine efficacy, and support the development of next-generation vaccines, therapeutics, and diagnostic assays.
Our peptide products are designed to support researchers investigating antigen-specific immune responses and developing next-generation therapeutic and vaccine strategies. Explore our off-the-shelp and ready-to-use catalog PepMix™ peptide pools for immune monitoring via T cell assays:
- PepMix™ Sudan Ebolavirus (GP/Uganda-00)
- PepMix™ Tai Forest Ebolavirus (NP)
- PepMix™ Zaire Ebola (GP/Mayinga-76)
- PepMix™ Bundibugyo Ebolavirus (Envelope GP/Uganda-07)
In addition to our off-the-shelf peptide offerings, we provide fully customizable solutions for:
Why work with JPT?
- Proven expertise in peptide synthesis and assay support
- High-quality peptide tools with reliable performance
- Flexible custom design options for infectious disease research
- Scientific support from project planning to data analysis